In a newly published correspondence, Italian rheumatology providers called into question whether recently published results from the DANBIO registry can be used to guide non-medical switching from reference etanercept (Enbrel) to biosimilar SB4 (Benpali) in patients with inflammatory diseases.
In a newly published correspondence, Italian rheumatology providers called into question whether recently published results from the DANBIO registry can be used to guide non-medical switching from reference etanercept (Enbrel) to biosimilar SB4 (Benpali) in patients with inflammatory diseases.
The DANBIO trial, results of which have previously been reported at scientific meetings, including the European League Against Rheumatism’s European Congress of Rheumatology 2017, reported on the real-world evidence of the effectiveness of switching from the reference to the biosimilar.1 In 2016, Denmark mandated a switch to the biosimilar from the reference among patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, providing an opportunity to compare treatment outcomes of those who switched and those who did not. The trial also compared retention against a historical cohort of reference etanercept users at 1 year.
In total, 1621 patients were switched, while 440 were not. The researchers reported that disease activity was unchanged at 3 months. One-year retention rates were 83% among the switch group (95% CI, 79%-87%) and 77% among the non-switch group (95% CI, 72%-82%). In the historic cohort, the retention rate was 90% (95% CI, 88%-92%).
During followup, 120 patients, or 7% of the switch group, transitioned back to the reference for reasons the DANBIO investigators termed “mainly subjective.”
In the correspondence on the DANBIO results2, the Italian authors wrote that “at first glance, the results show a good evidence of efficacy and safety of the procedure,” but that a careful reading of the study raises concerns.
According to the authors, the fact that the switched patients had longer previous treatment with etanercept and exposure to fewer previous biologic agents than the non-switched patients suggests that this group had less severe disease. Furthermore, some of the non-switched patients were receiving lower doses of etanercept than the switched patients, and potentially significant differences existed between the groups in terms of concomitant methotrexate use.
They also highlighted the fact that data on disease activity were limited to 3 months of followup, whereas discontinuation was evaluated at 1 year.
Finally, wrote the authors, “The strength of the results was greatly influenced by the nature of the study itself, that is to say mandatory switching without a well-structured study design, and, per se, these data do not constitute a solid base to ensure the rheumatologist for non-medical switching.”
In a reply3 to the correspondence, the authors of the original study stated that their paper is an example the ways in which observational studies can be a valuable supplement to randomized trials, and noted that they described the strengths and limitations of their study in detail, though the correspondents “largely ignore” that discussion.*
“For example,” wrote the authors, “the observed differences in the demographic and clinical characteristics of switchers compared with non-switchers illustrate that, despite a national guideline, the clinical decision to switch a patient or not was associated with certain patient characteristics.” This fact may reflect uncertainty among patients and providers on how to implement biosimilars into routine care, and it explains why patients who continued to receive the reference had lower retention than did those who switched.
They also noted that the nocebo effect may have had a role in the switched patients’ outcomes, and defended the 3-month followup period, saying that it allowed the use of patients as their own controls.
Finally, concluded the authors, their paper is a “well-balanced contribution to the ongoing discussion on real-world effectiveness of biosimilar etanercept in patients with inflammatory arthritis.”
*This article has been updated to include a discussion of the reply from Glintborg et al.
References
1. Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019;78:192-200. doi: 10.1136/annrheumdis-2018-213474.
2. Cantini F, Benucci M. Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: a possible fallout on non-medical switching [published online November 28, 2018]. Ann Rheum Dis. doi: 10.1136/annrheumdis-2018-214757.
3. Glintborg B, Loft AG, Omerovic E, et al. Response to: ‘Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching’ by Cantini and Benucci. 2018; 0:1-2. doi: 10.1136/annrheumdis-2018-214788.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.